Meeting Banner
Abstract #0530

Hyperpolarizied 13C MRSI is a better predictor of survival than tumor size in treated glioblastoma

Marina Radoul 1 , Myriam M. Chaumeil 1 , Pia Eriksson 1 , and Sabrina M. Ronen 1

1 Radiology and Biomedical Imaging, UCSF, San Francisco, CA, United States

Resistance to current therapy and recurrence is not only common in glioblastoma but also expected. PI3K/Akt/mTOR signaling pathway, activated in most glioblastoma, represents an important target in alternative therapeutic approach. In order to prepare for an upcoming clinical trial, the goal of this study was to expand upon previous studies, and to confirm reproducibility in different model systems and genetic background, and with a novel PI3K/Akt/mTOR inhibitor. We used hyperpolarized 13C MRSI, and 1H MRS, and to monitor the effect of the dual PI3K/mTOR inhibitor XL765 (SAR245409) and TMZ alone or in combination in GS-2 tumors in mice.

This abstract and the presentation materials are available to members only; a login is required.

Join Here